Autologous Platelet Lysate in Corneal Epithelial Defects

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-02-16

Study Completion Date

2019-01-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Patients diagnosed with persistent corneal epithelial ulcers will be treated with autologous platelet lysate.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Effect of Platelet Lysate on Corneal Epithelial Wound healing---the Collection of Human Serum From Volunteers

NCT02720146

Comparison of Epitheliotrophic Ability Between Human Serum and Commercialized Human Platelet- Cell and Animal Model

UNKNOWN

Platelet Rich Plasma as a Treatment For Resistant Corneal Ulcers

NCT05515731

Cornea Ulcer

COMPLETED PHASE4

Perforated Punctal Plugs for Treatment of Papillary Conjunctivitis in Otherwise Healthy Patients

NCT02503956

Epiphora Conjunctivitis

COMPLETED NA

Autologous Platelet-rich Plasma in the Treatment of Persistent Epithelial Defects

NCT03653650

Persistent Epithelial Defect

RECRUITING NA

Treatment of PED With AMT and Autologous Serum

NCT00238862

Corneal Epithelial Defect

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Autologous platelet lysate (PL) will be given to patients diagnosed with persistent corneal epithelial ulcers (PED) who are unresponsive to conventional therapy to promote the healing of PED. PL will be dispensed into sterile eye droppers, and these eye droppers will be stored ideally at -20C and thaw once for use, then will be kept in the refrigerator at +4C, to be taken in multiple doses.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Persistent Corneal Epithelial Defect

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Platelet Lysate

Autologous platelet lysate dispensed into eye droppers to be applied four times a day for a total of four weeks.

Group Type EXPERIMENTAL

Platelet Lysate

Intervention Type BIOLOGICAL

Eye drops of Platelet Lysate

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Platelet Lysate

Eye drops of Platelet Lysate

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Cognitive ability to understand and sign the consent form.
2. Corneal ulcers that did not re-epithelialise after 1 week of conventional treatment (therapeutic contact lenses, topical artificial tears, eye packs and antibiotic eye-drops).
3. Clinical indications: corneal ulcer due to caustic substances, corneal epitheliopathy, corneal lesions following cataract surgery, recurrent ulcerative keratitis, corneal lesions due to a foreign body.
4. Good compliance with the study regimen and availability for the duration of the entire study period.